Natco Pharma's Hyderabad API facility receives EIR from US FDA

Natco Pharma Limited has announced successful closure of inspection with the receipt of an Establishment Inspection Report (EIR) from the US Food and Drug Administration (FDA) for the inspection conducted at its Active Pharmaceutical Ingredient (API) facility in Mekaguda Village, near Hyderabad.

The inspection was conducted during the period August 5-9, 2019, the company said.

Comments

Popular posts from this blog

Updated Ph. Eur. Chapter on plastic containers

Dr. Stephen Hahn Nominated to Head FDA